| 24.79 0.18 (0.73%) | 12-07 14:21 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 28.95 |
1-year : | 33.81 |
| Resists | First : | 24.79 |
Second : | 28.95 |
| Pivot price | 23.49 |
|||
| Supports | First : | 22.88 |
Second : | 21.7 |
| MAs | MA(5) : | 24.45 |
MA(20) : | 23.22 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | 0.5 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 95.6 | D(3) : | 97.1 |
| RSI | RSI(14): 68.4 |
|||
| 52-week | High : | 25.38 | Low : | 2.89 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CANC ] has closed below upper band by 4.7%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 24.82 - 24.92 | 24.92 - 25 |
| Low: | 24.44 - 24.57 | 24.57 - 24.67 |
| Close: | 24.58 - 24.78 | 24.78 - 24.95 |
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.
Tue, 05 Dec 2023
Biden's Million Dollar Moonshot - $240 Million Is A Boon For Cancer Research, Will it be a Boost For Phar - Benzinga
Mon, 04 Dec 2023
Tema launches cardio-focused biotech ETF | ETF Strategy - ETF Strategy
Fri, 01 Dec 2023
EXCLUSIVE: Tema ETFs' Innovative Thematic Investing Approach Targets New Opportunities Beyond The Fads - - Benzinga
Tue, 28 Nov 2023
Active ETFs Appear Booming In 2023 — Tema ETFs Are Taking Them Into A New Direction - Tema Oncology ETF ( - Benzinga
Tue, 21 Nov 2023
Tema ETFs hops on weight-loss drug frenzy with its new cardiovascular fund - PharmaLive
Fri, 25 Aug 2023
Inside Tema ETFs' New Oncology ETF (CANC) - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|